PT2582683T - Tratamento da gota e de hiperuricemia - Google Patents

Tratamento da gota e de hiperuricemia

Info

Publication number
PT2582683T
PT2582683T PT117963249T PT11796324T PT2582683T PT 2582683 T PT2582683 T PT 2582683T PT 117963249 T PT117963249 T PT 117963249T PT 11796324 T PT11796324 T PT 11796324T PT 2582683 T PT2582683 T PT 2582683T
Authority
PT
Portugal
Prior art keywords
hyperuricemia
drop
treatment
Prior art date
Application number
PT117963249T
Other languages
English (en)
Portuguese (pt)
Inventor
Girardet Jean-Luc
Miner Jeffrey
D Quart Barry
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2582683(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of PT2582683T publication Critical patent/PT2582683T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT117963249T 2010-06-15 2011-06-14 Tratamento da gota e de hiperuricemia PT2582683T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24

Publications (1)

Publication Number Publication Date
PT2582683T true PT2582683T (pt) 2018-05-25

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117963249T PT2582683T (pt) 2010-06-15 2011-06-14 Tratamento da gota e de hiperuricemia

Country Status (19)

Country Link
US (3) US9216179B2 (OSRAM)
EP (1) EP2582683B1 (OSRAM)
JP (1) JP5964821B2 (OSRAM)
CA (1) CA2802407C (OSRAM)
CY (1) CY1120473T1 (OSRAM)
DK (1) DK2582683T3 (OSRAM)
ES (1) ES2670700T3 (OSRAM)
HR (1) HRP20180780T1 (OSRAM)
HU (1) HUE038265T2 (OSRAM)
LT (1) LT2582683T (OSRAM)
NO (1) NO2019008I1 (OSRAM)
PL (1) PL2582683T3 (OSRAM)
PT (1) PT2582683T (OSRAM)
RS (1) RS57275B1 (OSRAM)
SI (1) SI2582683T1 (OSRAM)
SM (1) SMT201800266T1 (OSRAM)
TR (1) TR201806828T4 (OSRAM)
WO (1) WO2011159732A1 (OSRAM)
ZA (1) ZA201300055B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402827B2 (en) 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
UA114304C2 (uk) * 2011-11-03 2017-05-25 Ардеа Біосайєнсіс, Інк. Спосіб зниження сироваткових рівнів сечової кислоти у людини
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
WO2015095703A1 (en) 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
CA3060185A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
US11447916B2 (en) 2018-10-26 2022-09-20 The Procter & Gamble Company Paper towel rolls
US12152347B2 (en) 2018-10-26 2024-11-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
JP7440934B2 (ja) * 2019-08-21 2024-02-29 国立大学法人 東京大学 Ａｂｃｃ１１阻害剤
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914611B2 (ja) 2003-12-26 2012-04-11 キッセイ薬品工業株式会社 ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2402011B1 (en) 2004-08-25 2012-11-14 Ardea Biosciences, Inc. S-triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
EP2120956A4 (en) 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
EA201270666A1 (ru) 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
JP2012502050A (ja) 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
MX2012007925A (es) 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
US9402827B2 (en) * 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
EP2627331A4 (en) * 2010-10-15 2014-03-12 Ardea Biosciences Inc METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
MX2013007505A (es) 2010-12-30 2013-08-01 Ardea Biosciences Inc Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1 -il)-4h-1,2,4-triazol-3-iltio)acetico y usos de los mismos.
US20140171424A1 (en) 2011-05-24 2014-06-19 Ardea Biosciences, Inc. Hypertension and hyperuricemia

Also Published As

Publication number Publication date
US20160143889A1 (en) 2016-05-26
RS57275B1 (sr) 2018-08-31
ES2670700T3 (es) 2018-05-31
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
DK2582683T3 (en) 2018-06-06
WO2011159732A1 (en) 2011-12-22
CY1120473T1 (el) 2019-07-10
PL2582683T3 (pl) 2018-08-31
SMT201800266T1 (it) 2018-07-17
NO2019008I1 (no) 2019-02-19
TR201806828T4 (tr) 2018-06-21
EP2582683B1 (en) 2018-03-21
ZA201300055B (en) 2018-05-30
US9216179B2 (en) 2015-12-22
JP5964821B2 (ja) 2016-08-03
CA2802407A1 (en) 2011-12-22
EP2582683A1 (en) 2013-04-24
JP2013528650A (ja) 2013-07-11
US20190015392A1 (en) 2019-01-17
HRP20180780T1 (hr) 2018-07-13
EP2582683A4 (en) 2014-04-30
SI2582683T1 (en) 2018-07-31
CA2802407C (en) 2018-01-23
HUE038265T2 (hu) 2018-10-29

Similar Documents

Publication Publication Date Title
PT2582683T (pt) Tratamento da gota e de hiperuricemia
BR112013002845A2 (pt) combinação de susbtâncias ativas
PT2640375T (pt) Método de tratamento da nefropatia induzida por contraste
PT2616087T (pt) Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
EP2534248A4 (en) Selective reduction of allelic variants
EP2534262A4 (en) SELECTIVE REDUCTION OF ALL-VARIANTS
HUE036439T2 (hu) Antimikrobiális készítmények és azok alkalmazási módszerei
EP2489334A4 (en) MEDICAL ENDOPROTHESIS
BR112013009496A2 (pt) artigos absorventes e métodos de fabricação dos mesmos
EP2785404A4 (en) CATHETER DEVICES AND METHOD THEREFOR
BR112012017441A2 (pt) compostos e métodos
BR112012026334A2 (pt) aparelho de cateter e introdutor de cateter
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
EP2549986A4 (en) MACROPHONE LEAVE TO MULTIPLE OBJECTIVES
ME02952B (me) Wnt antagonisti i metode tretiranja
IL232262A (en) Therapeutic agents and uses thereof
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
BR112014006291A2 (pt) composição e utilização da composição
BR112014031086A2 (pt) tratamento e prevenção de doenças cardiovasculares e trombose
BR112013002544A2 (pt) seção de armario e armario
BR112013009579A2 (pt) método e comprimido
SMT201600059B (it) Trattamento di infezioni da streptococco
HRP20181436T1 (hr) Postupak za primjenu nanočestica
EP2611440A4 (en) TREATMENT OF COCAINE
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER